Biolidics expects 'strong interest' in share placement
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
CANCER diagnostics company Biolidics is expecting "strong interest" for its share placement that could raise some S$3.1 million to fuel its business expansion and pursue new growth opportunities.
"While the current market conditions are choppy, we are encouraged that Biolidics' share placement exercise has attracted strong interest and we look forward to accelerating our plans to enable greater market outreach and accessibility to our pipe-line of diagnostic solutions," Biolidics' non-executive and non-independent chairman Jeremy Yee told BT on Monday.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Beijing’s calculated silence on the Iran war
DPM Gan warns of 3 structural shifts to the global system that will bring greater challenges – and opportunities
